| 1 |
Borowczak J, Szczerbowski K, Maniewski M, et al. The role of inflammatory cytokines in the pathogenesis of colorectal carcinoma-recent findings and review[J]. Biomedicines, 2022,10(7):1670.
|
| 2 |
Simpson D. Epidemiology of Castleman disease[J]. Hematol Oncol Clin North Am, 2018,32(1):1-10.
|
| 3 |
Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma[J]. Cancer, 1956,9(4):822-830.
|
| 4 |
Carbone A, Borok M, Damania B, et al. Castleman disease[J]. Nat Rev Dis Primers, 2021,7(1):84.
|
| 5 |
Dispenzieri A, Fajgenbaum DC. Overview of Castleman disease[J]. Blood, 2020,135(16):1353-1364.
|
| 6 |
Naka T, Nishimoto N, Kishimoto T. The paradigm of IL-6: from basic science to medicine[J]. Arthritis Res, 2002,4(Suppl 3):S233-S242.
|
| 7 |
Suneja S, Chidambaram M, Herzenberg AM, et al. Kidney involvement in multicentric castleman disease[J]. Am J Kidney Dis, 2009,53(3):550-554.
|
| 8 |
中华医学会血液学分会淋巴细胞疾病学组，中国抗癌协会血液肿瘤专业委员会，中国Castleman病协作组. 中国Castleman病诊断与治疗专家共识(2021年版)[J]. 中华血液学杂志，2021, 42(7): 529-534.
|
| 9 |
van Rhee F, Oksenhendler E, Srkalovic G, et al. International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease[J]. Blood Adv, 2020,4(23):6039-6050.
|
| 10 |
Zhang L, Zhao AL, Duan MH, et al. Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease[J]. Blood, 2019,133(16):1720-1728.
|
| 11 |
Zhang L, Li Z, Cao X, et al. Clinical spectrum and survival analysis of 145 cases of HIV-negative Castleman′s disease: renal function is an important prognostic factor[J]. Sci Rep, 2016,6:23831.
|
| 12 |
Ramaswami R, Lurain K, Polizzotto MN, et al. Characteristics and outcomes of KSHV-associated multicentric Castleman disease with or without other KSHV diseases[J]. Blood Adv, 2021,5(6):1660-1670.
|
| 13 |
Frizzera G, Peterson BA, Bayrd ED, et al. A systemic lymphoproliferative disorder with morphologic features of Castleman′s disease: clinical findings and clinicopathologic correlations in 15 patients[J]. J Clin Oncol, 1985,3(9):1202-1216.
|
| 14 |
Rieu P, Noёl LH, Droz D, et al. Glomerular involvement in lymphoproliferative disorders with hyperproduction of cytokines (Castleman, POEMS)[J]. Adv Nephrol Necker Hosp, 2000,30:305-331.
|
| 15 |
El Karoui K, Vuiblet V, Dion D, et al. Renal involvement in Castleman disease[J]. Nephrol Dial Transplant, 2011,26(2):599-609.
|
| 16 |
Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease[J]. Blood, 2005,106(8):2627-2632.
|
| 17 |
Xu D, Lv J, Dong Y, et al. Renal involvement in a large cohort of Chinese patients with Castleman disease[J]. Nephrol Dial Transplant, 2012,27 Suppl 3:iii119-iii125.
|
| 18 |
Donnan MD, Kenig-Kozlovsky Y, Quaggin SE. The lymphatics in kidney health and disease[J]. Nat Rev Nephrol, 2021,17(10):655-675.
|
| 19 |
Nechemia-Arbely Y, Barkan D, Pizov G, et al. IL-6/IL-6R axis plays a critical role in acute kidney injury[J]. J Am Soc Nephrol, 2008,19(6):1106-1115.
|
| 20 |
Xu C, Chang A, Hack BK, et al. TNF-mediated damage to glomerular endothelium is an important determinant of acute kidney injury in sepsis[J]. Kidney Int, 2014,85(1):72-81.
|
| 21 |
Al Otaibi T, Al Sagheir A, Ludwin D, et al. Post renal transplant Castleman′s disease resolved after graft nephrectomy: a case report[J]. Transplant Proc, 2007,39(4):1276-1277.
|
| 22 |
Mandel C, Silberstein M, Hennessy O. Case report: fatal pulmonary Kaposi′s sarcoma and Castleman′s disease in a renal transplant recipient[J]. Br J Radiol, 1993,66(783):264-265.
|
| 23 |
Cagirgan S, Cirit M, Ok E, et al. Castleman′s disease in a renal allograft recipient[J]. Nephron, 1997,76(3):352-353.
|
| 24 |
Vijgen S, Wyss C, Meylan P, et al. Fatal Outcome of multiple clinical presentations of human herpesvirus 8-related disease after solid organ transplantation[J]. Transplantation, 2016,100(1):134-140.
|
| 25 |
Lin J, Yu S, Wang R, et al. Multicentric Castleman′s disease in a renal allograft recipient: a case report and literature review[J]. J Int Med Res, 2020, 48(2):300060519897481.
|
| 26 |
Theate I, Michaux L, Squifflet JP, et al. Human herpesvirus 8 and Epstein-Barr virus-related monotypic large B-cell lymphoproliferative disorder coexisting with mixed variant of Castleman′s disease in a lymph node of a renal transplant recipient[J]. Clin Transplant, 2003,17(5):451-454.
|
| 27 |
Santos-Alonso C, Vaca Gallardo MA, Ferreira Bermejo M, et al. Multicentric Castleman′s disease in kidney transplant: a case report and literature review[J]. Nefrologia (Engl Ed), 2023,43 Suppl 2:103-105.
|
| 28 |
Liu AY, Nabel CS, Finkelman BS, et al. Idiopathic multicentric Castleman′s disease: a systematic literature review[J]. Lancet Haematol, 2016,3(4):e163-e175.
|
| 29 |
Fajgenbaum DC, Uldrick TS, Bagg A, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease[J]. Blood, 2017,129(12):1646-1657.
|
| 30 |
Yuan XG, Hu W, Chen FF, et al. Renal complications of Castleman′s disease: report of two cases and analysis of 75 cases[J]. Clin Exp Nephrol, 2011,15(6):921-926.
|
| 31 |
Leurs A, Gnemmi V, Lionet A, et al. Renal pathologic findings in TAFRO syndrome: is there a continuum between thrombotic microangiopathy and membranoproliferative glomerulonephritis? A case report and literature review[J]. Front Immunol, 2019,10:1489.
|
| 32 |
Mizuno H, Sawa N, Watanabe S, et al. The clinical and histopathological feature of renal manifestation of TAFRO syndrome[J]. Kidney Int Rep, 2020,5(8):1172-1179.
|
| 33 |
van Rhee F, Wong RS, Munshi N, et al. Siltuximab for multicentric Castleman′s disease: a randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2014,15(9):966-974.
|
| 34 |
Murakami K, Kobayashi T, Okubo K, et al. Successful renal transplantation for end-stage renal insufficiency developed in a patient with Castleman′s disease[J]. Transpl Int, 2013,26(7):e61-e62.
|
| 35 |
Matsunami M, Ubara Y, Sumida K, et al. The efficacy and safety of anti-interleukin-6 receptor monoclonal blockade in a renal transplant patient with Castleman disease: early post-transplant outcome[J]. BMC Nephrol, 2018,19(1):263.
|
| 36 |
Lee HR, An JM, Lee DR, et al. A case of Castleman disease that improved after kidney transplantation[J]. J Korean Soc Transplant, 2019,33(1):13-18.
|
| 37 |
Nagai M, Uchida T, Yamada M, et al. TAFRO syndrome in a kidney transplant recipient that was diagnosed on autopsy: a case report[J]. Front Med (Lausanne), 2021,8:747678.
|
| 38 |
Maitra S, Maitra D, Gowrishankar S. Successful renal transplant in Castleman disease - first case report from India[J]. Indian J Nephrol, 2023,33(4):296-299.
|
| 39 |
Shahidi H, Myers JL, Kvale PA. Castleman′s disease[J]. Mayo Clin Proc, 1995,70(10):969-977.
|
| 40 |
Cabezas L, Jouve T, Malvezzi P, et al. Tocilizumab and active antibody-mediated rejection in kidney transplantation: a literature review[J]. Front Immunol, 2022,13:839380.
|